Onstryv Now Approved for Parkinson’s Patients in Canada

Onstryv Now Approved for Parkinson’s Patients in Canada
Onstryv (safinamide) has been approved for the treatment of Parkinson’s disease in Canada, where roughly 100,000 individuals live with the disorder. The announcement was made by Quebec-based Valeo Pharma and Italian pharmaceutical conglomerate Zambon, the commercialization partner of Newron Pharmaceuticals, a biopharmaceutical company focused on the development of therapies for diseases of the central and peripheral nervous system. The agreement with Zambon ... read more
Source: Parkinson’s News TodayPublished on 2019-01-21By Mary Chapman